title: Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
abstract: Glioblastoma multiforme is a highy aggressive tumor that recurs despite resection, focal beam radiation, and temozolamide chemotherapy. ERC-1671 is an experimental treatment strategy that uses the patient's own immune system to attack the tumor cells. The authors report preliminary data on the first human administration of ERC-1671 vaccination under a single-patient, compassionate-use protocol. The patient survived for ten months after the vaccine administration without any other adjuvant therapy and died of complications related to his previous chemotherapies.
authors.affiliation: Associate Professor of Neurology and Neurosurgery at the University of California, Irvine in the City of Orange. dbota@uci.edu.
authors.forename: Daniela A
authors.initials: DA
authors.lastname: Bota
authors.affiliation: Neurosurgery Resident at the University of California, Irvine Medical Center in the City of Orange. danielaa@uci.edu.
authors.forename: Daniela
authors.initials: D
authors.lastname: Alexandru-Abrams
authors.affiliation: Laboratory Manager for Epitopoietic Research Corporation at the Scientific Park Crealys in Gemblous, Les Ines, Belgium. pretto@ercbelgium.eu.
authors.forename: Chrystel
authors.initials: C
authors.lastname: Pretto
authors.affiliation: Professor of Pathology at the Keck School of Medicine, University of Southern California, Los Angeles. hofman@usc.edu.
authors.forename: Florence M
authors.initials: FM
authors.lastname: Hofman
authors.affiliation: Chief Medical Officer of Epitopoietic Research Corporation and a Professor of Neurosurgery at the Keck School of Medicine, University of Southern California, Los Angeles. tcchen@usc.edu.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Chen
authors.affiliation: Neurological Oncology Nurse Practitioner in the Neurology Department of the University of California, Irvine Medical Center in the City of Orange. dfu@uci.edu.
authors.forename: Beverly
authors.initials: B
authors.lastname: Fu
authors.affiliation: Assistant Professor of Neurology at the University of California, Irvine Medical Center in the City of Orange. carrilj2@uci.edu.
authors.forename: Jose A
authors.initials: JA
authors.lastname: Carrillo
authors.affiliation: Chief Security Officer of Epitopoietic Research Corporation and a Professor of Immune Intervention in the Department of Cell Biology and Immunology at the Wageningen University in Netherlands. virgil.schijns@wur.nl.
authors.forename: Virgil Ejc
authors.initials: VE
authors.lastname: Schijns
authors.affiliation: Chief Executive Officer for Epitopoietic Research Corporation at the Scientific Park Crealys in Gemblous, Les Ines, Belgium and Chief Neurosurgeon, Department of Neurosurgery, Arlon Hospital, Belgium. tstath@hotmail.com.
authors.forename: Apostolos
authors.initials: A
authors.lastname: Stathopoulos
mesh_terms: D000328:Adult; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000276:immunology*; D005625:Frontal Lobe; D005909:Glioblastoma / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000276:immunology*; D016896:Treatment Outcome; D014612:Vaccines / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D000912:Antibodies, Neoplasm; D014612:Vaccines; D000068258:Bevacizumab